Markets:

Overview

News

Currencies

International

Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.8503 -0.0247 (-2.82%)

Streaming Delayed Price Updated: 12:10 PM EST, Feb 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Aprea Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial ↗

February 18, 2026

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.

Via Stocktwits

The market is filled with gapping stocks in Wednesday's session. ↗

February 18, 2026

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

January 30, 2026

Via Chartmill

Check out the stocks that are attracting the most attention and driving market activity. ↗

January 30, 2026

Via Chartmill

Aprea Therapeutics: Q4 Earnings Insights ↗

March 26, 2024

Via Benzinga

In today's session, these stocks are experiencing unusual volume. ↗

January 30, 2026

Via Chartmill

Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗

January 30, 2026

Via Chartmill

What's going on in today's after hours session ↗

January 29, 2026

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 31, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 15, 2024

Via Benzinga

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 12, 2024

APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 ↗

May 14, 2024

APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 04, 2024

Via Benzinga

APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗

March 26, 2024

APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday? ↗

March 11, 2024

FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 11, 2024

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

October 30, 2023

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

September 25, 2023

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

September 04, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 18, 2023

Via Benzinga

Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗

June 09, 2023

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 07, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

April 03, 2023

On Monday, 76 companies set new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023 ↗

March 10, 2023

Via Benzinga

Why Aprea Therapeutics Shares Hit A New 52-Week Low Today ↗

February 23, 2023

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock. What Else?

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 23, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 22, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 19, 2023

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.